PEGylation of therapeutic proteins

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biotechnology Journal

• Publication date

  2010-01-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/biot.200900218PMID 20069580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Size exclusion chromatography with Corona charged aerosol detector for the analysis of polyethylene glycol polymer.

  2009cited by this paper
• Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG.

  2009cited by this paper
• Emerging PEGylated drugs

  2009cited by this paper
• Engineered protein scaffolds as next-generation antibody therapeutics.

  2009cited by this paper
• Correlations between in vitro potency of polyethylene glycol-protein conjugates and their chromatographic behavior.

  2009cited by this paper
• Single domain antibodies: promising experimental and therapeutic tools in infection and immunity

  2009cited by this paper
• PEG-modified biopharmaceuticals

  2009cited by this paper
• PEG-modified biopharmaceuticals.

  2009cited by this paper
• Display scaffolds: protein engineering for novel therapeutics.

  2008cited by this paper
• Size of Pegylated Protein Conjugates Studied by Various Methods

  2008cited by this paper
• Advances in PEGylation of important biotech molecules: delivery aspects

  2008cited by this paper
• Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.

  2008cited by this paper
• Formulation of Neulasta (pegfilgrastim).

  2008cited by this paper
• Releasable PEGylation of proteins with customized linkers.

  2008cited by this paper
• Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase.

  2008cited by this paper
• The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.

  2008cited by this paper
• PEG-uricase in the management of treatment-resistant gout and hyperuricemia.

  2008cited by this paper
• Obstacles and pitfalls in the PEGylation of therapeutic proteins.

  2008cited by this paper
• Designing PEGylated therapeutic molecules: advantages in ADMET properties

  2008cited by this paper
• Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.

  2007cited by this paper
• Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.

  2007cited by this paper
• Alternative non-antibody scaffolds for molecular recognition.

  2007cited by this paper
• Polymer-drug conjugation, recent achievements and general strategies

  2007cited by this paper
• Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites.

  2007cited by this paper
• Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.

  2007cited by this paper
• Comparison of strong anion-exchangers for the purification of a PEGylated protein.

  2007cited by this paper
• Properties, production, and applications of camelid single-domain antibody fragments

  2007cited by this paper
• Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals.

  2007cited by this paper
• Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules

  2007cited by this paper
• Site-specific pegylation of G-CSF by reversible denaturation.

  2007cited by this paper
• Nanobodies in therapeutic applications.

  2007cited by this paper
• Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

  2006cited by this paper
• Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

  2006cited by this paper
• Ultrafiltration characteristics of pegylated proteins

  2006cited by this paper
• N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

  2006cited by this paper
• Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

  2006cited by this paper
• GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.

  2006cited by this paper
• Site-specific PEGylation of native disulfide bonds in therapeutic proteins

  2006cited by this paper
• PEG-proteins: Reaction engineering and separation issues

  2006influential reference
• Characterization of synthetic polymers by MALDI-MS

  2006cited by this paper
• Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

  2005cited by this paper
• Reproducible preparation and effective separation of PEGylated recombinant human granulocyte colony-stimulating factor with novel "PEG-pellet" PEGylation mode and ion-exchange chromatography.

  2005cited by this paper
• In vivo incorporation of an alkyne into proteins in Escherichia coli.

  2005cited by this paper
• Creating the next generation of protein therapeutics through rational drug design.

  2005cited by this paper
• Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids.

  2005cited by this paper
• A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.

  2005cited by this paper
• A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific PEGylation

  2005cited by this paper
• Making site-specific PEGylation work: Purification and analysis of PEGylated protein pharmaceuticals present many challenges

  2005cited by this paper
• Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.

  2005cited by this paper
• Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins

  2005cited by this paper
• The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

  2004influential reference
• Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins.

  2004cited by this paper
• Effect of an anti‐PDGF‐β‐receptor‐blocking antibody on restenosis in patients undergoing elective stent placement

  2003cited by this paper
• Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates.

  2003cited by this paper
• Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases.

  2003cited by this paper
• Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

  2003cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Mono-N-terminal poly(ethylene glycol)-protein conjugates.

  2002cited by this paper
• Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.

  2002cited by this paper
• Chemistry for peptide and protein PEGylation.

  2002cited by this paper
• Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

  2002cited by this paper
• Enzymatic procedure for site-specific pegylation of proteins.

  2002cited by this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Immunological properties of uricase conjugated to neutral soluble polymers.

  2001cited by this paper
• Microbial degradation of polyethers

  2001cited by this paper
• Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins.

  2001cited by this paper
• Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.

  2000cited by this paper
• Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation.

  2000cited by this paper
• Therapeutic antibody fragments with prolonged in vivo half-lives

  1999cited by this paper
• Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins.

  1998cited by this paper
• Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein Conjugates

  1997cited by this paper
• Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

  1992cited by this paper
• Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins.“

  1992cited by this paper
• Succinimidyl Carbonates of Polyethylene Glycol: Useful Reactive Polymers for Preparation of Protein Conjugates

  1991cited by this paper
• Suppression of Antibody Responses by Conjugates of Antigens and Monomethoxypoly(Ethylene Glycol)

  1991cited by this paper
• Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers.

  1990cited by this paper
• Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase.

  1988cited by this paper
• Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

  1984cited by this paper
• Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins.

  1983cited by this paper
• Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol.

  1977cited by this paper
• Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.

  1977cited by this paper

• Microwave-assisted hydrolysis for the physicochemical characterization of functional methacrylic polymers and their bioconjugates.

  2026cites this paper
• Molecular engineering of designer diabetes therapeutics.

  2026cites this paper
• Recent advances in polymeric nanoparticles for the treatment of hepatic diseases

  2025cites this paper
• A shark VNAR with cross-species reactivity for serum albumin: Implications for long-term therapeutic applications.

  2025cites this paper
• Molecular dynamics simulation of polyethylene glycol-based deep eutectic solvents: Microstructure, dynamics and potentials for curcumin delivery

  2025cites this paper
• Preclinical Investigations of a Novel PEGylated Long-Acting Human Growth Hormone

  2025cites this paper
• PEPITEM and its tripeptide pharmacophores: Mechanisms of bone regulation and therapeutic potential in health and disease.

  2025cites this paper
• Biologics, Biosimilars, and Biobetters: Therapeutic Innovations Reshaping Modern Medicine

  2025cites this paper
• Strategic Approaches for Overcoming Peptide and Protein Drug Limitations

  2025cites this paper
• 3,4-Dihydroquinolizinium Ring, the Core Structure of Quinocidin, As a Cysteine-Selective Electrophile.

  2025cites this paper
• Purification of a Fc-Fusion Protein with [Bathophenathroline:metal] Complexes

  2025cites this paper
• Different strategies to make biobetters: physicochemical, pharmacodynamics, and pharmacokinetic aspects came into focus.

  2025cites this paper
• Research status and future perspectives of IL-27 in the treatment of stroke (Review)

  2025cites this paper
• Delivering living medicines with biomaterials

  2025cites this paper
• Cloning, Expression, Characterization and in silico studies of L-asparaginase from Vibrio sp. (GBPx3).

  2025cites this paper
• Tick saliva molecules as potential immunomodulatory therapeutics.

  2025cites this paper
• Enhancing stability and catalytic activity of urate oxidase using natural deep eutectic solvent: insights from experimental and computational approaches.

  2025cites this paper
• Industrial Production of PEGylated L-asparaginase: Process Design and Techno-economic Assessment Through Simulation

  2025cites this paper
• Pharmacokinetic considerations and strategies for antibody-based therapeutics

  2025cites this paper
• Advances in Stimuli-Responsive Peptide-Polymer Carriers for Mitochondrial Therapeutics.

  2025cites this paper
• The Art of PEGylation: From Simple Polymer to Sophisticated Drug Delivery System

  2025cites this paper
• Chromatography media and purification processes for complex and super-large biomolecules: A review.

  2025cites this paper
• Innovative Formulation Platform: Paving the Way for Superior Protein Therapeutics with Enhanced Efficacy and Broadened Applications

  2024cites this paper
• Peptide-based therapeutics: challenges and solutions

  2024cites this paper
• Pegylation enhances the anti-osteoporosis activity of acacetin in both ovariectomized and LPS-stimulated mice.

  2024cites this paper
• Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis.

  2024cites this paper
• Systemic Treatment with Fas-Blocking Peptide Attenuates Apoptosis in Brain Ischemia

  2024cites this paper
• Dual Functional Microcapsule based on Monodisperse Short PEG Amphiphile for Drug Encapsulation and Protein Affinity Controlled Release.

  2024cites this paper
• Development of an enabling platform biotechnology for the production of proteins

  2024cites this paper
• Biomimetic Multilayered Lipid Nanovesicles for Potent Protein Vaccination

  2024cites this paper
• Enzyme-Polymer Conjugates with Photocleavable Linkers for Control Over Protein Activity.

  2024cites this paper
• PEGylation of silver nanoparticles via Berginia Ciliata aqueous extract for biological applications

  2024cites this paper
• Opportunities and challenges of RiPP-based therapeutics.

  2024cites this paper
• Polyethylene glycol-mediated functionalization of nanodelivery systems for improving their pharmacokinetic profile and anticancer efficacy

  2024cites this paper
• Radical Ring-Opening Polymerization: Unlocking the Potential of Vinyl Polymers for Drug Delivery, Tissue Engineering, and More.

  2024cites this paper
• Scaling analytical RP-HPLC to semi-preparative for fractionation and characterization of pegfilgrastim oxidized variants.

  2024cites this paper
• Enhancing leuprolide penetration through enterocytes via the ER-Golgi pathway using lipophilic complexation.

  2024cites this paper
• A Comparative Study of PEGylated Cobalt Oxide Nanoparticles (Co3O4-NPs) and Cobalt Sulfide Nanoparticles (Co9S8-NPs) for Biological and Photocatalytic Applications

  2024cites this paper
• Polyethylene glycol has immunoprotective effects on sciatic allografts, but behavioral recovery and graft tolerance require neurorrhaphy and axonal fusion

  2024cites this paper
• Optimizing Pharmacological and Immunological Properties of Therapeutic Proteins Through PEGylation: Investigating Key Parameters and Their Impact

  2024cites this paper
• Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol

  2024cites this paper
• Exploring Protein-Based Carriers in Drug Delivery: A Review

  2024cites this paper
• Evolution of Peptide Biopharmaceuticals

  2023cites this paper
• A guide to complement biology, pathology and therapeutic opportunity

  2023cites this paper
• Treatment-induced and pre-existing anti-PEG antibodies: Prevalence, clinical implications, and future perspectives.

  2023cites this paper
• Smart nanoparticles for cancer therapy

  2023cites this paper
• Matrix Metalloproteinase-Responsive Delivery of PEGylated Fibroblast Growth Factor 2.

  2023cites this paper
• Lipidization as a tool toward peptide therapeutics

  2023cites this paper
• Modification and delivery of enkephalins for pain modulation.

  2023cites this paper
• Site-specific PEGylation of recombinant tissue-type plasminogen activator.

  2023cites this paper
• New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy

  2023cites this paper
• PEGylation of Human Vascular Endothelial Growth Factor.

  2023cites this paper
• Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4

  2023cites this paper
• Amphiphilic Cell-Penetrating Peptides Containing Arginine and Hydrophobic Residues as Protein Delivery Agents

  2023cites this paper
• Design and Application of Hybrid Polymer-Protein Systems in Cancer Therapy

  2023cites this paper
• In Vitro Properties and Pharmacokinetics of Temporarily PEGylated Onc72 Prodrugs

  2023cites this paper
• Current status and prospect for future advancements of long-acting antibody formulations

  2023cites this paper
• Role of the gradient slope during the product internal recycling for the multicolumn countercurrent solvent gradient purification of PEGylated proteins.

  2023cites this paper
• Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells

  2023cites this paper
• Advanced Formulation Approaches for Proteins.

  2023cites this paper
• Evolution of Peptide Drug Biopharmaceutics

  2023cites this paper
• Negr1-Derived Peptides Trigger ALK Degradation and Halt Neuroblastoma Progression In Vitro and In Vivo

  2023cites this paper
• 3D-Printed Microcubes for Catalase Drug Delivery

  2023cites this paper
• Conjugation and encapsulation of L-asparaginase: an effective strategy for augmenting enzyme potential for anticancer activity

  2023cites this paper
• Amino acid-mPEGs: Promising excipients to stabilize human growth hormone against aggregation

  2023cites this paper
• Polyethylene Glycol-Mediated Directional Conjugation of Biological Molecules for Enhanced Immunoassays at the Point-of-Care

  2023cites this paper
• Emerging opportunities for C3 inhibition in the eye.

  2022cites this paper
• Advocation and advancements of EPR effect theory in drug delivery science: A commentary.

  2022cites this paper
• Fast and high-resolution fractionation of positional isomers of a PEGylated protein using membrane chromatography.

  2022cites this paper
• Polymeric Nanotubes as Drug Delivery Vectors—Comparison of Covalently and Supramolecularly Assembled Constructs

  2022cites this paper
• Development of Peptide Biopharmaceuticals in Russia

  2022cites this paper
• Therapeutic peptides: current applications and future directions

  2022cites this paper
• Receptor-Targeted Dual pH-Triggered Intracellular Protein Transfer.

  2022cites this paper
• Special Section on Pharmacokinetics and ADME of Biological Therapeutics – Minireview A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation

  2022cites this paper
• The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases.

  2022cites this paper
• Complex Polymer Architectures Using Ring-Opening Metathesis Polymerization: Synthesis, Applications, and Practical Considerations

  2022cites this paper
• Progress of albumin-polymer conjugates as efficient drug carriers

  2022cites this paper
• A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation

  2022cites this paper
• A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes.

  2022cites this paper
• Subvisible particles derived by dropping stress enhance anti-PEG antibody production and clearance of PEGylated proteins in mice.

  2022cites this paper
• Pegylation – in search of balance and enhanced bioavailability

  2022cites this paper
• Polymers and polymeric hybrids for targeted drug delivery

  2022cites this paper
• New Strategy for Improving Protein Therapeutics by Mechano-bioconjugation

  2022cites this paper
• An insight on lipid nanoparticles for therapeutic proteins delivery

  2022cites this paper
• Design and economic investigation of a Multicolumn Countercurrent Solvent Gradient Purification unit for the separation of an industrially relevant PEGylated protein.

  2022cites this paper
• Mechano-bioconjugation Strategy Empowering Fusion Protein Therapeutics with Aggregation Resistance, Prolonged Circulation, and Enhanced Antitumor Efficacy.

  2022cites this paper
• Derivatization with fatty acids in peptide and protein drug discovery

  2022cites this paper
• Synthesis and characterization of chitosan-PVA hydrogel containing PEGylated recombinant epidermal growth factor on cell culture for wound healing substitute

  2022cites this paper
• The current research status and strategies employed to modify food-derived bioactive peptides

  2022cites this paper
• Molecular simulations of zwitterlation-induced conformation and dynamics variation of glucagon-like peptide-1 and insulin.

  2022cites this paper
• Special Section on Pharmacokinetics and ADME of Biological Therapeutics — Minireview Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives S

  2022cites this paper
• Synthesis and Studies of Bulky Cycloalkyl α,β-Dehydroamino Acids that Enhance Proteolytic Stability.

  2022cites this paper
• Albumin Binding Nanofitins, a new scaffold to extend half-life of Biologics - a case study with exenatide peptide.

  2022cites this paper
• Protein PEGylation: Navigating Recombinant Protein Stability, Aggregation, and Bioactivity

  2022cites this paper
• Bottom-up design of hydrogels for programmable drug release.

  2022cites this paper
• Enzymatic dispersion of biofilms: An emerging biocatalytic avenue to combat biofilm-mediated microbial infections

  2022cites this paper
• Cell membrane-camouflaged DOX-loaded β-glucan nanoparticles for highly efficient cancer immunochemotherapy.

  2022cites this paper
• Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives

  2022cites this paper
• A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent

  2021cites this paper
• Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity

  2021cites this paper